Technical Analysis for CLBS - Caladrius Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 3.87 3.20% 0.12
CLBS closed up 3.2 percent on Tuesday, March 19, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical CLBS trend table...

Date Alert Name Type % Chg
Mar 19 Bollinger Band Squeeze Range Contraction 0.00%
Mar 19 Lower Bollinger Band Walk Weakness 0.00%
Mar 19 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 19 Lower Bollinger Band Touch Weakness 0.00%
Mar 18 Bollinger Band Squeeze Range Contraction 3.20%
Mar 18 BB Squeeze + Lower Band Touch Range Contraction 3.20%
Mar 18 Lower Bollinger Band Touch Weakness 3.20%
Mar 15 Bearish Engulfing Bearish -1.28%
Mar 15 Fell Below 20 DMA Bearish -1.28%

Older signals for CLBS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Banking Biopharmaceutical Cancer Diabetes Immunotherapy Cancer Immunotherapy Metastatic Melanoma Clinical Services Acute Myocardial Infarction Treatment Of Metastatic Melanoma
Is CLBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.65
52 Week Low 3.05
Average Volume 29,354
200-Day Moving Average 4.9206
50-Day Moving Average 4.5153
20-Day Moving Average 3.9868
10-Day Moving Average 3.8725
Average True Range 0.2395
ADX 24.95
+DI 19.6908
-DI 31.6253
Chandelier Exit (Long, 3 ATRs ) 3.6415
Chandelier Exit (Short, 3 ATRs ) 4.3285
Upper Bollinger Band 4.3022
Lower Bollinger Band 3.6714
Percent B (%b) 0.31
BandWidth 15.822213
MACD Line -0.1822
MACD Signal Line -0.198
MACD Histogram 0.0158
Fundamentals Value
Market Cap 36.48 Million
Num Shares 9.43 Million
EPS -11.27
Price-to-Earnings (P/E) Ratio -0.34
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.24
Resistance 3 (R3) 4.20 4.04 4.18
Resistance 2 (R2) 4.04 3.95 4.06 4.16
Resistance 1 (R1) 3.96 3.89 4.00 3.99 4.14
Pivot Point 3.79 3.79 3.82 3.81 3.79
Support 1 (S1) 3.71 3.70 3.75 3.75 3.60
Support 2 (S2) 3.55 3.64 3.56 3.58
Support 3 (S3) 3.46 3.55 3.56
Support 4 (S4) 3.50